Latest Breaking News On - Trevi therapeutics daily - Page 1 : comparemela.com

Frazier Life Sciences Management L P Purchases 500,000 Shares of Trevi Therapeutics, Inc (NASDAQ:TRVI)

Frazier Life Sciences Management L.P. lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,381,090 shares of the company’s stock after purchasing an additional 500,000 shares during […]

Thomas sciasciaRodman renshawTrevi therapeutics company profileExchange commissionNeedham companyTrevi therapeutics incFrazier life sciences managementSg americas securitiesTrevi therapeuticsFree reportTherapeutics stock downGet free reportVisit holdingschannelTrevi therapeutics daily

WealthTrust Axiom LLC Sells 30,000 Shares of Trevi Therapeutics, Inc (NASDAQ:TRVI)

WealthTrust Axiom LLC Sells 30,000 Shares of Trevi Therapeutics, Inc (NASDAQ:TRVI)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Exchange commissionTrevi therapeutics incWealthtrust axiomNeedham companySilverarc capital managementTrevi therapeutics company profileTrevi therapeuticsFree reportTrust axiomCapital managementTherapeutics trading downGet free reportVisit holdingschannelTrevi therapeutics daily

WealthTrust Axiom LLC Has $85,000 Holdings in Trevi Therapeutics, Inc (NASDAQ:TRVI)

WealthTrust Axiom LLC Has $85,000 Holdings in Trevi Therapeutics, Inc (NASDAQ:TRVI)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Sg americas securitiesTrevi therapeutics incWealthtrust axiomNeedham companyTrevi therapeuticsFree reportTrust axiomTherapeutics stock downGet free reportVisit holdingschannelTrevi therapeutics daily

Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $8.00 price objective on the stock. Separately, Oppenheimer reissued an outperform rating and issued a $9.00 price target on shares of Trevi Therapeutics in a […]

Geode capital managementVanguard group incNeedham companyBlackrock incTrevi therapeutics incOpaleye management incTrevi therapeuticsFree reportGet free reportStreet corpCapital managementTrevi therapeutics daily

Trevi Therapeutics (TRVI) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $8.00 price target on shares of Trevi Therapeutics in […]

Nuveen asset managementNeedham companyVanguard group incTrevi therapeutics incTrevi therapeuticsFree reportStreet corpAsset managementGet free reportTrevi therapeutics dailyNasdaq trviReiterated ratingOppenheimer holdings inc